Solitary Fibrous Tumor: Causes, Symptoms, and Treatment

Solitary fibrous tumors (SFTs) are rare soft-tissue growths driven by a specific genetic accident: two genes on chromosome 12, called NAB2 and STAT6, fuse together inside a single cell, and the resulting hybrid gene pushes that cell to multiply into a tumor. Most SFTs grow slowly, and many are cured by surgery alone, but a meaningful minority behave aggressively, spreading to distant organs years or even decades after the original tumor was removed. Because SFTs can arise almost anywhere in the body and often produce no symptoms until they are large, understanding what to look for and how they are managed matters for anyone who has been diagnosed or is waiting on a biopsy result.

What Causes a Solitary Fibrous Tumor

SFTs belong to a family of tumors that arise from mesenchymal cells, the connective-tissue cells that form structures like blood vessels, fat, and fibrous tissue. The defining event is a fusion between the NAB2 gene and the STAT6 gene, both of which sit close together on chromosome 12.¹ Under normal circumstances, NAB2 acts as a brake on certain growth-promoting pathways by repressing a family of transcription factors called EGR. When NAB2 fuses with STAT6, that brake gets flipped into an accelerator, converting NAB2 from a repressor into an activator of EGR-driven genes.² This single genetic rearrangement appears to be the initiating event for SFTs and is found in essentially all confirmed cases, making it the tumor’s molecular signature.

No strong environmental or lifestyle risk factors have been identified. Unlike some cancers linked to smoking, chemical exposures, or inherited syndromes, SFTs appear to arise from a random, spontaneous DNA rearrangement. The fusion is not inherited from a parent, and having one SFT does not mean your children face elevated risk. The tumor can occur at any age and in either sex, though population data suggest it is most commonly diagnosed in middle-aged adults.³

Where SFTs Grow

SFTs were originally recognized in the lining around the lungs (the pleura), where they were sometimes called “solitary fibrous tumors of the pleura.” For decades, a related-looking tumor called hemangiopericytoma (HPC) was considered a separate diagnosis. The discovery that both tumors share the same NAB2-STAT6 fusion confirmed they are the same disease, and the World Health Organization merged them into a single entity.⁴ If you encounter the term hemangiopericytoma in older medical records, it refers to what is now classified as SFT.

While the pleura remains a classic location, SFTs actually appear throughout the body. They have been documented in the abdomen, pelvis, extremities, head and neck, orbit (the bony socket around the eye), and the meninges surrounding the brain and spinal cord. This anatomic versatility is one reason the tumor can be difficult to suspect before a biopsy: a slow-growing mass in the thigh raises a different set of possibilities than one found on a CT scan of the abdomen, yet both may turn out to be SFTs.

Symptoms and How SFTs Present

Many SFTs are discovered incidentally, meaning they show up on imaging performed for an unrelated reason. The tumor tends to grow slowly and can reach a substantial size before causing trouble. Symptoms, when they do occur, depend heavily on location. Pleural SFTs often cause cough, chest pain, or shortness of breath; large abdominal SFTs may press on nearby organs and cause vague discomfort or a palpable mass; and tumors in the extremities may simply appear as a firm, painless lump under the skin.

In the chest, some patients develop digital clubbing, where the fingertips become rounded and swollen, along with joint pain caused by a condition known as hypertrophic pulmonary osteoarthropathy. This combination has been described in roughly ten to twenty percent of patients with pleural SFTs.⁴ Both the clubbing and the joint symptoms typically resolve after the tumor is removed.

Doege-Potter Syndrome and Dangerous Low Blood Sugar

One of the more striking things an SFT can do is drive blood sugar dangerously low. This paraneoplastic phenomenon, called Doege-Potter syndrome, occurs in fewer than five percent of SFT cases.⁵ The tumor produces large quantities of incompletely processed insulin-like growth factor 2 (often called “big IGF-2”), a molecule that mimics insulin. Big IGF-2 floods the bloodstream, driving glucose into tissues, suppressing glucagon secretion, and shutting down the liver’s ability to release stored sugar. The result is recurrent episodes of severe hypoglycemia that can cause confusion, seizures, and loss of consciousness.⁶

Because hypoglycemia has many possible causes, Doege-Potter syndrome can be misdiagnosed initially as an insulin-secreting pancreatic tumor or as a medication side effect. A key laboratory clue is that insulin levels are low or suppressed during the hypoglycemic episodes, which is the opposite of what you see when the pancreas itself is the problem. In patients with a known or suspected SFT, recurrent low blood sugar should raise immediate suspicion for this syndrome. Removing or debulking the tumor usually resolves the hypoglycemia.

How SFTs Are Diagnosed

Imaging is typically the first step. On CT and MRI, SFTs tend to appear as well-defined masses that light up brightly with contrast dye because they have a rich blood supply.⁷ Larger tumors may show areas of internal bleeding, cyst formation, or dead tissue, which gives them a patchwork appearance on scans.⁸ None of these imaging features are unique to SFTs, however, so a tissue sample is needed to confirm the diagnosis.

A biopsy examined under the microscope will show spindle-shaped cells arranged in a characteristic “patternless pattern,” a somewhat paradoxical term pathologists use to describe the haphazard way SFT cells organize themselves. To pin down the diagnosis, pathologists rely on a panel of immunohistochemical stains. The most valuable marker is nuclear STAT6, which reflects the underlying NAB2-STAT6 fusion. In one study of 53 confirmed SFTs, nuclear STAT6 staining was positive in about 96 percent of cases. Other commonly positive markers include CD34 (positive in roughly 89 percent), CD99, and Bcl-2.⁹ Using these markers together provides strong diagnostic confidence.¹⁰

Preoperative biopsy does not always yield the correct answer. In one single-center study, about 17 percent of patients received a preoperative diagnosis that did not match the final SFT pathology.¹¹ Because of this, surgery frequently serves as both a diagnostic and a therapeutic procedure: the tumor is removed, and the final diagnosis comes from examining the entire specimen.

Assessing Aggressiveness

Not all SFTs behave the same way. Some are slow-growing, essentially benign masses that never return after surgery. Others recur locally, and a subset spreads to distant sites such as the lungs, liver, or bone. Predicting which tumors will cause trouble is one of the central challenges in managing this disease.

Researchers have developed a risk-scoring system that uses four variables to estimate the likelihood of future metastasis: the patient’s age, the size of the tumor, the mitotic count (how many dividing cells are seen under the microscope), and the presence of tumor necrosis (dead tissue within the tumor).¹² Older patients, larger tumors, higher mitotic counts, and necrosis all push the score higher. This scoring system helps oncologists decide how closely a patient needs to be monitored after surgery and whether additional treatment should be considered.

Population-level survival data reinforce that higher-grade tumors carry a substantially worse prognosis. In one large analysis of more than 800 SFT cases, age over 51, high pathologic grade, and metastatic disease at diagnosis were all independently associated with shorter survival. The five-year disease-specific survival across all comers was about 66 percent, and the ten-year figure was roughly 53 percent, though these numbers encompass a wide spectrum from indolent to aggressive tumors.³ For patients with low-risk, completely resected tumors, outcomes are considerably better than those averages suggest.

Surgery as the Primary Treatment

Complete surgical removal with clear margins is the cornerstone of SFT treatment.¹³ “Clear margins” means the surgeon removes enough tissue around the tumor that a pathologist sees no cancer cells at the edges of the specimen. When clear margins are achieved, many patients are cured outright. The specific surgical approach depends on where the tumor is located: a pleural SFT may require video-assisted thoracic surgery or an open thoracotomy, while an abdominal SFT might need a laparotomy.

One surgical challenge is the tumor’s rich blood supply. Large SFTs can bleed substantially during removal, and some surgical teams use preoperative embolization, a procedure that blocks the tumor’s feeding arteries before the operation, to reduce blood loss. In cases where the tumor has grown into or around critical structures, achieving clear margins may require removing portions of adjacent organs or tissues, a decision that involves careful weighing of the risk of incomplete resection against the morbidity of a more aggressive operation.

The Role of Radiation Therapy

Because SFTs are rare, there are no large randomized trials definitively proving that radiation improves outcomes. The evidence comes from retrospective studies and multi-center collaborations, and it points in a consistent direction: adding radiation after surgery reduces the risk of the tumor coming back at the original site.

A retrospective study from the Global Solitary Fibrous Tumor Initiative found that surgery plus perioperative radiation was associated with a significantly lower risk of local progression compared with surgery alone, even after accounting for differences in mitotic count and margin status. However, this improvement in local control did not translate into a clear overall survival benefit.¹⁴ A study from the Rare Cancer Network echoed this, finding that the addition of radiation improved local control and disease-free survival, particularly for SFTs located in the extremities or superficial trunk.¹⁵ Another analysis found excellent local control when surgery and radiation were combined.¹⁶

In practice, radiation tends to be recommended when margins are close or positive, when the tumor has high-risk features like a high mitotic count, or when the tumor is in a location where local recurrence would be especially problematic. For small, low-grade tumors removed with wide clear margins, radiation is often deferred.

Systemic Therapy for Advanced Disease

When an SFT cannot be fully removed by surgery or has spread to distant sites, systemic drug therapy enters the picture. Traditional chemotherapy agents used against other soft-tissue sarcomas have limited effectiveness in SFTs. One retrospective analysis of trabectedin, a marine-derived chemotherapy drug, showed disease control (partial responses plus stable disease) in about 82 percent of patients, with a median time before the disease progressed of roughly 12 months.¹⁷ Those numbers reflect disease stabilization more than dramatic tumor shrinkage; true partial responses were uncommon.

The more promising drug class for advanced SFTs targets the tumor’s blood vessel network. Because SFTs are highly vascular, drugs that block the formation of new blood vessels can starve the tumor of its supply lines. Pazopanib, an oral anti-angiogenic agent already approved for soft-tissue sarcomas, has shown activity in advanced SFTs, and because of its existing approval it is widely accessible.¹⁸ Sunitinib, another anti-angiogenic drug, has also demonstrated antitumor activity. In a study of ten SFT patients treated with sunitinib, six achieved partial responses by modified criteria, and five of those responses lasted longer than six months.¹⁹ These agents are not cures, but they can meaningfully slow disease progression and buy time.

Research into newer targets continues. Because the NAB2-STAT6 fusion drives the disease, there is strong conceptual rationale for therapies that directly block the downstream EGR-pathway signaling it activates.² The role of immunotherapy is also being explored, though results so far have been limited and the therapeutic potential remains uncertain.²⁰

SFTs Inside the Skull

Intracranial SFTs (sometimes still called meningeal hemangiopericytomas in older literature) deserve special attention because they behave differently from SFTs in many other locations. These tumors arise from the meninges, the membranes covering the brain, and can closely mimic meningiomas on imaging. The distinction matters because the two have very different long-term trajectories.

A propensity-matched comparison found that patients with intracranial SFTs had significantly worse progression-free survival after five years compared with meningioma patients. Beyond five years, disease-specific survival was also worse for the SFT group.²¹ The study also identified age at diagnosis, mitotic count, and whether the patient received postoperative radiation as factors influencing outcomes. These tumors have a well-documented tendency to relapse, which makes long-term surveillance particularly important.²²

Why Long-Term Follow-Up Matters So Much

One of the most unusual features of SFTs, and one that distinguishes them from many other soft-tissue tumors, is how late they can recur. While some cancers that are going to come back do so within the first two or three years, SFTs have been documented recurring a decade or more after apparently successful surgery. A case report of an SFT arising in bone illustrated this point starkly: the patient developed lung metastases only on long-term follow-up, emphasizing that an initial clean bill of health does not mean the disease is permanently gone.²³

This late-recurrence pattern means that most sarcoma specialists recommend indefinite or very long surveillance with periodic imaging, often continuing for at least ten to fifteen years and sometimes for life. The exact schedule varies by risk level: a small, low-grade tumor removed with wide margins may be followed with annual imaging, while a high-grade tumor with close margins might warrant scans every few months initially, gradually spacing out over time. For patients with recurrent disease, the dynamics shift: recurrent SFTs tend to recur again more quickly and are more likely to progress systemically, with one small series finding that two-thirds of patients operated on for recurrent SFTs relapsed again.¹¹

Getting Care at a Specialized Center

Because SFTs are rare, most community oncologists and surgeons will see only a handful over an entire career. This rarity has practical consequences. Pathologists unfamiliar with the tumor may not think to order the STAT6 stain that clinches the diagnosis, and surgeons without sarcoma experience may not prioritize the wide margins that reduce recurrence risk. Multi-disciplinary tumor boards at sarcoma referral centers regularly discuss cases like these, integrating input from surgical oncologists, radiation oncologists, medical oncologists, and pathologists who have seen enough SFTs to recognize the subtleties.

If you have been diagnosed with an SFT or if a biopsy suggests the possibility, seeking a second opinion at a center with sarcoma expertise is worth the effort. This is especially true for tumors in challenging locations such as the skull base, retroperitoneum, or mediastinum, where the surgical approach has a major impact on both tumor control and quality of life. Even if the surgery ultimately happens closer to home, having the pathology reviewed and the treatment plan vetted by a specialist team can meaningfully influence your outcome.